CD19 and acute lymphoblastic leukemia: As an example, the product ARI-0001 or CART19-BE-01, currently included in the list of PRIME medicines, is an anti-CD19 CAR against B-cell malignancies, which was approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) under HE to treat adult patients (>25 years old) with r/r ALL [21] in 2021.